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ABSTRACT: 
BACKGROUND: The value of adjuvant radiotherapy in triple negative breast cancer 
(TNBC) remains unclear. A systematic review and meta-analysis was conducted in 
TNBC patients to assess survival and recurrence outcomes associated with 
radiotherapy following either breast conserving therapy (BCT) or post-mastectomy 
radiotherapy (PMRT).  
METHODS: Four electronic databases were searched from January 2000 to 
November 2015 (PubMed, MEDLINE, EMBASE and Web of Science). Studies 
investigating overall survival and/or recurrence in TNBC patients according to 
radiotherapy administration were included. A random effects meta-analysis was 
conducted using mastectomy only patients as the reference.       
RESULTS: Twelve studies were included. The pooled hazard ratio (HR) for 
locoregional recurrence comparing BCT and PMRT to mastectomy only was 0.61 
(95% confidence interval [CI] 0.41-0.90) and 0.62 (95% CI 0.44-0.86), respectively. 
Adjuvant radiotherapy was not significantly associated with distant recurrence. The 
pooled HR for overall survival comparing BCT and PMRT to mastectomy only was 
0.57 (95% CI 0.36-0.88) and HR 1.12 (95% CI 0.75, 1.69). Comparing PMRT to 
mastectomy only, tests for interaction were not significant for stage (p=0.98) or age 
at diagnosis (p=0.85). However, overall survival was improved in patients with late-
stage disease (T3-4, N2-3) pooled HR 0.53 (95% CI 0.32-0.86), and women <40 
years, pooled HR 0.30 (95% CI 0.11-0.82).  
CONCLUSIONS: Adjuvant radiotherapy was associated with a significantly lower 
risk of locoregional recurrence in TNBC patients, irrespective of the type of surgery. 
While radiotherapy was not consistently associated with an overall survival gain, 
benefits may be obtained in women with late-stage disease and younger patients.  
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INTRODUCTION:  
Triple negative breast cancer (TNBC) accounts for 10-15% of all breast cancer [1] 
and is defined by an immunohistochemical absence of expression for oestrogen 
receptor (ER), progesterone receptor (PR) and human epidermal growth factor 
receptor 2 (HER2) [2]. Patients with TNBC typically present with high-grade disease 
and often an early pattern of recurrence [1,3–5]. With no drug-targetable receptors 
[6], chemotherapy continues to be the mainstay of treatment in TNBC patients.   
 
At present, there are no specific clinical guidelines for treating TNBC [7,8]. Like other 
breast cancers, locoregional management of TNBC comprises breast conserving 
therapy (BCT) i.e.: breast conserving surgery followed by radiotherapy, or 
mastectomy (with or without adjuvant radiotherapy). While there is international 
consensus on indications for postmastectomy radiotherapy (PMRT) [8–10], these 
guidelines do not account for breast cancer subtype.  
 
A recent systematic review of over 12,000 patients by Lowery et al [11] examined 
locoregional recurrence risk after breast cancer surgery according to receptor 
phenotype. The authors compared TNBC patients to other non-TNBC patients and 
found that TNBC was associated with an increased risk of locoregional recurrence 
following BCT, as well as mastectomy. The findings  of this study are important, as it 
serves to highlight that TNBC is an aggressive disease with a higher risk of local 
recurrence compared to other breast cancer subtypes, irrespective of the 
locoregional therapy. Nevertheless, this systematic review does not provide 
evidence on whether the surgical procedures per se, or adjuvant radiotherapy 
therein, have any prognostic role in TNBC. In order to address the ongoing debate of 
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whether adjuvant radiotherapy confers any recurrence-free or survival benefit in 
patients with TNBC [12–16], there needs to be a direct comparison between various 
locoregional treatment strategies within patients with triple negative disease. 
 
Previous studies examining recurrence and survival outcomes in patients with TNBC 
according to locoregional treatment status have produced conflicting results [17–29]. 
It is likely that several of these studies were underpowered due to their small sample 
size [19–21,30]. Moreover, potentially important survival differences may exist 
depending on disease stage [18,22] and age at diagnosis [18]. We therefore 
conducted a meta-analysis to determine the risk of locoregional/distant recurrence, 
and overall survival associated with BCT or PMRT, versus mastectomy alone in 
patients with TNBC. Such analysis is needed for informed decision-making regarding 
the optimum locoregional treatment strategies in TNBCs.  
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METHODOLOGY:  
Search strategy    
This meta-analysis was conducted in accordance to the preferred reporting items for 
systematic reviews and meta-analyses (PRISMA) statement [31]. Four electronic 
databases (MEDLINE, EMBASE, PubMED and Web of Science) were searched 
from January 2000 to November 2015. The year 2000 was chosen as a cut-off, as 
this is the date from which molecular subtypes of breast cancer were first defined 
[32]. No other date or language restrictions were imposed. The search strategy 
(Table 2, online only), developed in MEDLINE, was comprised of several key search 
terms combined with the boolean operators AND/OR aligned to relevant medical 
subject headings, and included various terms for ‘breast cancer’, ‘breast conserving 
therapy/mastectomy’, ‘triple negative’ and ‘survival/recurrence’ outcomes.  
 
Study eligibility  
Observational studies and randomised controlled trials reporting hazard ratios (HRs), 
odds ratios (ORs) or relative risks (RRs) and associated 95% confidence intervals 
(CIs) for overall and/or locoregional/distant recurrence were included if they 
examined 1) breast cancer patients with triple negative (non-metastatic) disease at 
diagnosis who 2) clearly stratified survival/recurrence endpoints by the type of 
surgery (mastectomy or breast conserving therapy) received and 3) in which 
radiotherapy status was reported. All studies in which standardised therapy was 
administered were considered eligible regardless of the exact chemotherapeutic 
regimens (i.e.: neo-adjuvant/adjuvant) or radiotherapy protocols. A concerted effort 
was made to contact the authors of all potentially relevant studies to obtain effect 
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estimates or counts of events by surgical/radiotherapy exposure status that were not 
reported in the original paper.        
 
Data collection and extraction  
Each electronic database was searched by the principal reviewer (MO’R). Three 
reviewers then indendently scanned the titles and abstracts of all identified papers 
after duplicate removal (MO’R, NB, LM). The full papers from all potentially relevant 
studies were then sourced and read. Data extraction was undertaken by two 
reviewers (MO’R, NB) using a pre-defined excel spreadsheet, recording detailed 
information on the origin of the study (country and year), characteristics of the 
population under study (study size, age and follow-up time, stage of disease), 
survival estimates and associated 95% CIs and covariates for adjustment in the 
analysis. The methodological quality of included cohort studies was assessed using 
the Newcastle-Ottawa scale [33] and the Cochrane risk of bias tool was used for 
assessing randomised trials [34].   
 
Statistical analysis  
Effect estimates and associated 95% CIs comparing survival and recurrence 
outcomes stratified by surgical type (BCT or PMRT) were extracted from all relevant 
papers. Wherever possible we reported on multivariable adjusted effect estimates. 
Within studies from which an unadjusted effect estimate could be derived from the 
raw counts of exposed and unexposed patients, corresponding effect estimates were 
estimated by calculating a rate ratio in Stata using the ‘CSI’ command. Individual 
study authors were also contacted to obtain frequencies not reported in the original 
article. One study [24], through personal communication with the authors, provided 
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anonymous individual patient data which enabled its inclusion in specific subgroup 
analysis. The principal quantitative synthesis involved a comparison of BCT and 
PMRT. Mastectomy only patients were used as the reference group in all analyses. 
Study-specific effect estimates were pooled using a random effects model, as 
described by DerSimonian and Laird [35], to account for both within-study sampling 
error (variance) and between-study variation. The degree of statistical heterogeniety 
was assessed using the Cochrane’s Q test and the percentage variation in the effect 
estimate attributable to this heterogeniety was assessed using the I-squared statistic 
[36]. In post-hoc sensitivity analysis, the influence of each individual study was 
assessed by excluding each in turn and re-running the analyses monitoring for 
changes in heterogeniety and the overall summary estimate. Given the reported 
survival differences with adjuvant radiotherapy in more advanced disease [18,22] 
and younger patients [18], planned subgroup analyses by age group (<40, 40-64, 
≥65 years) and early (T1-2, N0-1) and late stage (T3-4, N2-3) disease were also 
undertaken.  Begg’s rank correlation test [37] and Egger’s linear regression test [38] 
were conducted to investigate potential small study effects or other publication 
biases. Stata IC v. 11.0 (StataCorp, College Station, TX, USA) was used for all 
analyses.  
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RESULTS: 
A total of 1,539 papers were identified. Of these, 1,473 were clearly irrelevant from 
the initial screening of their title and abstract. Upon closer inspection of the 
remaining 66 papers (for which the full text articles were sought), only 12 met the 
criteria for inclusion. Justification for subsequent study exclusions are documented in 
Figure 1.  
 
Table 1 summarises the characteristics of the 12 included studies. Of these, the 
majority (9 out of 10) were retrospective cohort studies and two were randomised 
controlled trials. The methodological quality of the included cohort studies was 
moderate to high with a mean score of six out of a possible nine (range 4 to 8; Table 
3, online only). There appeared to be a low risk of bias in the included randomised 
controlled trials across all domains (Table 4, online only); however, blinding of 
surgical procedure and radiotherapy receipt was not practicable in this context. The 
median follow-up period ranged between 1.9 to 7.2 years across the studies and 
locoregional recurrence was the most commonly assessed endpoint in 9 studies 
[17,19–23,25,29,30]. The median age at diagnosis ranged from 50 to 59 years with 
the largest study including 1,138 TNBC patients [18], and the two smallest [19,30] 
consisted of 62 TNBC patients each. In 5 studies, patients who had undergone neo-
adjuvant chemotherapy prior to surgery were excluded [17,19,25,29,30]. The 
majority of studies were conducted in the USA or Asia.  
 
Locoregional recurrence  
Six studies [17,19–21,29,30] examined locoregional recurrence in a total of 1,795 
patients. Comparing BCT to mastectomy only, the pooled HR was 0.61 (95% CI 
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0.41, 0.90), Figure 2. Seven studies (2,487 patients) [17,19–23,25] compared PMRT 
to mastectomy only, the pooled HR was 0.62 (95% CI 0.44, 0.86), Figure 2. There 
was no evidence of heterogeniety in either analyses. In subgroup analysis only two 
studies [17,29] (1,114 patients) examined locoregional recurrence in early-stage (T1-
2, N0) disease. Comparing BCT to mastectomy only, the pooled HR was 0.55 (95% 
CI 0.32-0.95), with no evidence of heterogenity. Two additional studies [22,23] 
compared PMRT to mastectomy alone and locoregional recurrence risk among 
women with late-stage disease (T3-4, N2-3), with a pooled HR of 0.32 (95% CI 0.16-
0.65). No significant heterogeniety was present.  No studies reported on the 
influence of age at diagnosis on locoregional recurrence by radiotherapy 
administration.  
 
Distant recurrence 
Five studies (1,615 patients) reported on distant recurrence [17,19,21,29,30]. The 
pooled HR comparing BCT to mastectomy only patients was HR 0.88 (95% CI 0.63, 
1.25), Figure 3. There was no evidence of heterogeniety. Four studies (1,059 
patients) [17,19,21,23] compared PMRT to mastectomy only, the pooled HR was 
1.40 (95% CI 0.63, 3.10), and significant heterogeniety was detected Pheterogeniety 
=0.000, I2 = 87.6%, Figure 3. Only one study [29] examined distant recurrence in 
patient’s with early-stage disease. It was not possible to examine the impact of late-
stage disease (T3-4, N2-3) or age at diagnosis and the risk of distant recurrence by 
radiotherapy receipt.  
 
Overall survival  
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Six studies (3,184 patients) compared BCT to mastectomy only for overall survival 
[17–19,21,24,29]. The pooled HR was 0.57 (95% CI 0.36-0.88), Figure 4; moderate 
heterogeniety was present (Pheterogeniety =0.07, I2 = 50.5%). There was little difference 
when the analysis was restricted to four studies [17,18,24,29] with multivariable 
adjusted estimates HR 0.57 (95% CI 0.31-1.02).  Comparing PMRT to mastectomy 
only, the pooled HR from seven studies (3,219 patients) [17–19,21,24,27,29] was 
1.12 (95% CI 0.75, 1.69) Figure 4. Again, significant heterogeniety was present 
(Pheterogeniety =0.001, I2 = 77.0%). Four studies (1,973 patients) examined overall 
survival in early-stage (T1-2, N0) disease [17,18,24,29], comparing BCT to 
mastectomy only, with a pooled HR of 0.74 (95% CI 0.43-1.29), Pheterogeniety =0.031, I2 
= 66.1%, Figure 5 (online only). Two further studies [18,24] additionally provided an 
estimate of overall survival comparing PMRT to mastectomy only within T1-2, N0 
tumours; pooled HR 1.10 (95% CI 0.33-3.64). Both of the above studies [18,24] also 
examined overall survival in relation to late stage disease (T3-4, N2-3). The pooled 
HR comparing BCT and PMRT to mastectomy only was 0.25 (95% CI 0.10-0.62) and 
0.53 (95% CI 0.32-0.86) respectively; no statistical heterogeniety was detected. 
There was no statistically significant interaction between disease stage and 
BCT/PMRT on overall survival, Pinteraction= 0.983. Combining data from two studies 
[18,24], the effect of age at diagnosis on overall survival comparing PMRT and BCT 
to mastectomy only was examined, the corresponding pooled effect estimates were 
HR 0.30 (95% CI 0.11-0.82) and HR 0.22 (95% CI 0.04, 1.13) age <40 years, HR 
0.76 (95% CI 0.37-1.58) and HR 0.38 (95% CI 0.11, 1.31) aged 40-64 years, and HR 
0.67 (95% CI 0.14-3.18) and HR 0.79 (95% CI 0.22-2.76) aged ≥65 years 
respectively, Figure 6 (online only). No statistically significant interaction was 
detected, Pinteraction =0.847.  
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Sensitivity analyses  
For each comparison undertaken (i.e.: BCT/PMRT versus mastectomy only), in post-
hoc sensitivity analysis we excluded each study in turn to monitor for individual study 
effects on heterogeniety and the overall effect estimate. One relatively large (n=768) 
study of stage T1-3, N0-3 patients [17], had a strong influence on the observed effect 
estimates for several of the outcomes studied. For locoregional recurrence (6 
studies) comparing BCT to mastectomy only, removal of this one study [17], resulted 
in a slight attenuation of the overall effect estimate HR 0.72 (95% CI 0.46, 1.15), 
Pheterogeniety =0.823, I2 = 0.0%. For distant recurrence comparing PMRT to 
mastectomy only (4 studies), the exclusion of this same study [17], attenuated the 
pooled estimate HR 0.94 (95% CI 0.58-1.52) Pheterogeniety =0.196 and explained much 
of the observed heterogeniety (I2 =38.7%). For overall survival, comparing PMRT to 
mastectomy only (7 studies), exclusion of the study by Abdulkarim et al [17], again 
attenuated the pooled effect estimate HR 0.86 (95% CI 0.72-1.02) and significantly 
lowered heterogeniety (I2 = 7.6%, P=0.363). The systematic removal of other 
studies, including those of different study designs (i.e.: randomised trial versus 
cohort study) or from conference proceedings only,  failed to materially alter the 
overall pooled effect estimates or heterogeniety (data not shown).   
 
Publication bias 
Begg and Egger tests were undertaken to assess for publication and other small 
study biases. There was no evidence of publication/small-study bias in comparisons 
where locoregional recurrence or overall survival were study outcomes (data not 
shown). However, in comparisons of BCT to mastectomy alone for distant 
recurrence (5 studies), there was some evidence of publication or other small-study 
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bias (Begg p=0.221, Egger p=0.009). The resulting Egger regression plot showed 
deviation of the intercept from zero, indicating marked asymmetry with relatively few 
studies of higher precision.  
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DISCUSSION: 
There is a paucity of studies that have examined the prognostic impact of adjuvant 
radiotherapy in breast cancer patients with triple negative disease. The findings from 
this study show that administration of adjuvant radiotherapy confers a locoregional 
recurrence-free survival benefit in TNBC, irrespective of the type of surgery initially 
received. The administration of adjuvant radiotherapy was not significantly 
associated with distant recurrence, and there was no consistent overall survival 
benefit observed between locoregional treatment groups.  
 
Previous studies evaluating the value of radiotherapy in TNBC patients have shown 
conflicting results. A study of 768 patients from a comprehensive cancer centre in a 
single Canadian province, reported an increased risk of locoregional recurrence in 
T1-2, N0 TNBC patients treated with mastectomy only in comparison to those 
receiving BCT, suggesting that adjuvant radiotherapy may be an important factor in 
optimising local control; however there was no observed difference in overall survival 
[17]. Conversely, a retrospective study of 646 T1-2, N0 TNBC patients in the USA, 
reported no significant difference in locoregional recurrence between patients 
receiving BCT or mastectomy [29]. Several other studies which also included 
patients with more advanced cancer stages showed that BCT administration was 
associated with lower risk of locoregional recurrence than mastectomy alone, albeit 
not achieving statistical significance [20,21,30]. It is however likely that these studies 
were underpowered due to their small sample size.  
 
A prospective, randomised controlled multi-centre study, which was conducted in the 
era before TNBC was recognised as a specific entity, had documented that in 
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women with stage I or stage II TNBC undergoing mastectomy, administration of 
radiotherapy combined with chemotherapy, was associated with superior local 
recurrence-free survival compared to chemotherapy alone [27].  In a study from the 
Danish Breast Cancer Co-operative Group 82 b and c trials, Kyndi et al [23] 
examined the impact of breast cancer subtypes on PMRT response. The trial 
included data from 152 TNBC patients with high-risk disease (i.e.: either positive 
lymph nodes or T3/4 disease), 74 of which were randomised to receive PMRT. In 
multivariable analysis, the authors reported significantly smaller locoregional 
recurrence reductions in the TNBC subtype. While the authors suggested that this 
was perhaps a result of increased radioresistance in these tumours, these results 
may be explained by the higher mitotic index and aggressive clinical course of 
TNBCs, which may not necessarily be radioresistant [17]. Moreover, the 
predisposition to BRCA mutations in TNBC patients, which renders the tumour 
defective in DNA repair, has been argued as a mechanism for increased 
radiosensitivity [12]. A prospective single institutional study of 77  TNBC patients with 
T1-4, N0-2 tumours in the USA [21] had found that women who did not undergo 
PMRT had a significantly higher risk of locoregional recurrence. Corroborating these 
findings, a retrospective analysis of 553 TNBC patients from a single institution in 
Shanghai, Chen et al [22] also reported that the addition of PMRT to the treatment of 
patients with high-risk disease (stage T3-4, N2-3) led to superior locoregional 
recurrence outcomes; a finding which compliments the results of the present meta-
analysis.         
 
Recently, the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) 
conducted a meta-analysis of individual patient data from 22 randomised trials 
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including over 8,000 women [39]. Whilst not specifically reporting on patients with 
TNBC, this study found that PMRT among women with one to three positive axillary 
nodes, significantly reduced not only locoregional, but also distant recurrence, even 
when systemic therapy was given [39]. In line with this evidence, Kyndi et al [23] 
using data from the Danish Breast Cancer Co-operative Group trials, reported a 
significant increased risk of distant recurrence among TNBC patients not receiving 
PMRT. However, other studies have shown non-significant increased risks of distant 
recurrence in patients undergoing PMRT compared to mastectomy only [17,19,21]. 
In pooled analysis in the present study, distant recurrence was not significantly 
associated with either PMRT or BCT in comparison to patients recieving mastectomy 
only. The absence of any clear effect may be attributable to the small number of 
studies (low power) examining this endpoint.  
 
In this meta-analysis, radiation therapy does not appear to be consistently 
associated with an overall survival benefit in TNBCs. This is in view of the fact that 
we only observed a higher overall survival in patients subjected to BCT compared to 
mastectomy only, but not in patients undergoing PMRT. Steward et al [24] conducted 
a retrospective investigation of 468 patients with stage I-III (T1-4, N0-3) TNBC from a 
single USA centre. Similar to the current findings, the authors only found a survival 
benefit associated with radiotherapy in women undergoing breast conservation and 
not in those receiving mastectomy. This observation may be partly explained by the 
underlying differences in patient selection for type of surgery, whereby breast 
conserving surgery is typically indicated for patients with smaller tumours (T1-2) [40], 
and conceivably a better baseline prognosis [41].  This notion is supported by the 
findings of the present meta-analysis, wherein the initial survival benefit associated 
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with BCT compared to mastectomy in all-stage patients was attenuated and non-
significant within patients with very early stage disease (T1-2, N0 tumours).  
 
Based on the pooled HRs from the current meta-analysis there was a suggestion of 
a stronger overall survival benefit associated with BCT compared to mastectomy 
alone in women with late-stage disease (T3-4, N2-3) and younger age at diagnosis 
(<40 years). However, these findings should be interpreted with caution as we found 
no evidence of effect modification by stage or age, perhaps owing to the small 
number of studies available for stratified analyses. Further prospective studies in 
these subgroups are warranted. Whilst the mechanism for a preferential overall 
survival benefit of adjuvant radiotherapy in younger patients is unknown, one 
potential explanation may be that the presence of underlying BRCA gene mutation in 
these patients may have influenced RT response [42], as it is suggested that 
tumours that arise in BRCA carriers are likely to be more sensitive to the effects of 
ionizing radiation [43].  
 
A strength of the present analysis was the stratification of TNBC patients according 
to locoregional management (i.e.: BCT versus PMRT), as patients with a less 
favourable prognosis may be more likely to receive PMRT than BCT [41], making it 
inappropriate to classify the BCT and PMRT as a composite adjuvant radiotherapy 
group. In planned subgroup analysis, we attempted to ascertain differences in 
response to adjuvant radiotherapy by both stage of disease and age at diagnosis. 
The average follow-up time among the 12 included studies in this systematic review 
was 4.6 years (range 1.9-7.2), although in two studies follow-up was under 3 years 
[20,21]. Accounting for other known prognostic factors, it has been previously 
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reported that TNBCs exhibit a distinctive early pattern of recurrence, peaking at 2-3 
years, with the majority occurring within the first 5 years [44]. Therefore, the follow-
up periods in the majority of the included studies in the present review are likely 
adequate to determine their intended survival endpoints.  
 
The limitations of this systematic review principally relate to the fact that it is not a 
meta-analysis of individual patient data and that there were only a small number of 
contributing studies, which were often limited by the lack of details reported in the 
original publication. Wherever possible, efforts were made to contact the authors of 
the original paper to obtain stratified frequencies of events by type of surgery and 
radiotherapy receipt. In all, 16 authors were contacted by e-mail for data requests. Of 
the 7 replies received, only 2 authors provided additional information [19,24]. Of 
note, two of the studies included in the present analysis were from conference 
proceedings only [20,30] and two were randomised controlled trials [23,27]. 
However, their exclusion in post-hoc sensitivity analysis did not materially alter the 
pooled findings. The majority of included studies were single institution, 
retrospective, non-randomised study designs with likely differences in the clinical and 
pathologic characteristics of their patient populations (Table 1). This may have 
inevitably contributed to the observed high heterogeneity in certain estimates.  
 
It is also important to note that the TNBC subtype per se, is not in itself an indication 
for post-mastectomy radiotherapy [45], and that the decision to irradiate is influenced 
by many factors including tumour-related prognostic features (i.e.: involved margins, 
larger tumour size, positive lymph node status, lymphovascular invasion), patient-
related factors (i.e.: socioeconomic status, patient preference/values) and health 
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system-related factors (physician-preference/values, availability of radiotherapy 
machines). Whilst some of these aspects were accounted for in the analyses of 
several studies included in the current meta-analysis, other factors are inherently 
difficult to capture and may have impacted our findings to some extent.  
 
While it is conceivable that systemic treatment may have varied between the 
different settings where the studies in this review were conducted, it is felt that this 
may not have influenced the results to a great extent. This review addresses patients 
with non-metastatic triple negative breast cancer, in whom the (global) standard of 
care for neoadjuvant/adjuvant treatment during the study period was anthracycline 
+/- taxane based chemotherapy, to which TNBCs have been shown to be particularly 
sensitive [46]. Dose intensity may well have differed between the different study 
populations, particularly in Asia [47]. However, other than specifying chemotherapy 
regimen, this information was not available in the studies included in the current 
review. Only five studies reported the exclusion of patients who had undergone neo-
adjuvant chemotherapy prior to surgery [17,19,25,29,30]. This may be particularly 
important to bear in mind, as the response to neo-adjuvant treatment may 
differentially affect the patterns of recurrence and overall survival in TNBC patients 
[48]. Many included studies whilst reporting on the raw frequencies of outcomes by 
type of surgery and radiotherapy use, did not conduct multivariable survival analysis. 
In such studies, we calculated an unadjusted risk ratio, which unfortunately leaves 
open the potential for confounding.   
 
In summary, this systematic review and meta-analysis shows that adjuvant 
radiotheray, irrespective of the extent of initial breast surgery, is associated with 
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locoregional recurrence benefits in patients with TNBC. However radiotherapy, was 
not consistently associated with an improvement in overall survival. While subgroup 
analyses seem to suggest that adjuvant radiotherapy may be more strongly 
associated with an overall survival gain in patients with T3-4,N2-3 tumors, as well as 
in women aged less than 40 years, these observations need to be interpreted with 
caution in light of the small number of  contributing studies, and absence of effect 
modification by stage, and age at diagnosis. There is hence a need, for future 
prospective clinical trials to assess the role of adjuvant radiotherapy in TNBC 
subgroups who currently fall outside the remit of conventional radiotherapy 
guidelines. In future work, the authors plan to conduct an individual participant data 
meta-analysis to improve understanding on the continued debate of adjuvant 
radiotherapy in TNBC.  
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LEGENDS: 
Table 1: Characteristics of included studies  
Figure 1: Flow diagram illustrating study identification, selection and inclusion. 
Figure 2: Forest plots of locoregional recurrence comparing breast conserving 
therapy or post mastectomy radiotherapy to patients receiving mastectomy only. 
Figure 3: Forest plots of distant recurrence comparing breast conserving therapy or 
post mastectomy radiotherapy to patients receiving mastectomy only. 
Figure 4: Forest plots of overall survival comparing breast conserving therapy or 
post mastectomy radiotherapy to patients receiving mastectomy only. 
Figure 5 (online only): Forest plot of overall survival comparing breast conserving 
therapy to mastectomy only in a subgroup of patients with early and late-stage 
disease. 
 
Figure 6 (online only): Forest plot of overall survival comparing post-mastectomy 
radiotherapy and breast conserving therapy to mastectomy only by age group 
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Table 1: Characteristics of included studies  
 
Study ID & 
country/region 
Study design TNBC study population Study 
size 
(TNBC 
cases) 
Age 
(years) 
 Follow-
up time 
(years) 
Stage 
of 
disease 
Survival 
estimates 
Chemotherapy 
 
Adjustments 
Abdulkarim 
2011 [17] 
Canada 
Retrospective 
cohort study 
Newly diagnosed TNBC 
from Jan 1998 and Dec 
2008 in a single cancer 
centre (Alberta). 
768 
 
Median: 
56 
 
Median: 
7.2  
T1-3, 
N0-2 
 
OS, LRR, 
DM 
 
Excluded 
patients with 
NCT.  
85% CT 
Tumour size, grade, LN 
status, LVI, chemotherapy 
Bhoo-Pathy 
2015 [18] Asia 
Retrospective 
cohort study 
Non-metastatic TNBC 
patients from hospital-based 
cancer registries in five 
Asian centres (University 
Malaya Medical Centre, 
Malaysia, National Cancer 
Centre, Singapore, National 
University Hospital, 
Singapore, Tan Tock Seng 
Hospital, Singapore, and 
Queen Mary and Tung Wah 
Hospital, Hong Kong) 
diagnosed between 2006 
and 2011. 
1,138 Median: 
53 
Median: 
3.6 
T1-4, 
N0-3 
 
OS 13% NCT 
75.8% CT  
Centre (UMMC, NUH, 
NCCS, TTSH, QMTWH), age 
at diagnosis, race, tumour 
size at diagnosis, number of 
positive axillary lymph 
nodes, tumour grade (low, 
moderate, high), surgical 
margins (free, involved), 
lymphovascular invasion 
(present, absent), neo-
adjuvant chemotherapy (yes, 
no) and adjuvant 
chemotherapy administration 
and regimen (none, first 
generation, second 
generation, third generation).  
Chen 2013 [22] 
China 
Retrospective 
cohort study 
TNBC from a single 
institution (Fudan University, 
Shanghai Cancer Centre, 
Shanghai China) diagnosed 
between the 1st January 
2000 and the 31st July 2007.  
553 52 5.4 T1-4, 
N0-3 
LRR, DFS 88% CT 
% NCT NR 
Age, PMRT treatment, 
Lymphovascular invasion, 
grade, tumour size, lymph 
node status (4 or more 
positive vs. one to three 
positive), and chemotherapy 
regimen.  
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Study ID & 
country/region 
Study design TNBC study population Study 
size 
(TNBC 
cases) 
Age 
(years) 
 Follow-
up time 
(years) 
Stage 
of 
disease 
Survival 
estimates 
Chemotherapy 
 
Adjustments 
Cruz 2014 [19] 
Brazil 
Retrospective 
cohort study 
TNBC patients submitted to 
surgical treatment from Jan 
2000 and Dec 2005 at one 
University hospital (Hospital 
Santa Casa de Misericordia 
de Porto Alegre, Brazil). 
62 NR 
 
Average: 
4.8  
 
T1-4, 
N0-3 
 
OS, LRR, 
DM 
Excluded 
patients with 
NCT.  
85.7% CT 
Unadjusted  
Dragun 2011 
[21] USA 
Prospective 
cohort study  
Prospective study of non-
metastatic TNBC patients 
undergoing treatment 
between 2004-2009 from the 
University of Louisville's 
James Graham Brown 
Cancer Centre. 
77 
 
 
50 1.9 T1-T4, 
N0-N2 
 
OS, LRR, 
DM 
32.5% NCT 
55.8% CT 
 
Unadjusted  
Eastman 2012* 
[20] USA 
Retrospective 
cohort study 
Retrospective review of 
patients with TNBC 
undergoing treatment 
between Jan 2004 and Jan 
2011 in a comprehensive, 
multidisciplinary breast 
oncology programme at the 
University of Texas, Dallas, 
USA.  
180 NR Median: 
2.5 
T1-4, 
N0-3  
LRR NR Unadjusted  
Kyndi 2008 [23] 
Denmark 
Randomised 
Controlled 
Trial  
Patients diagnosed from 
1982 to 1990 with high-risk 
breast cancer enrolled onto 
the Danish Breast Cancer 
Collaborative Group Trial 82 
B & C (pre-menopausal and 
menopausal women 
respectively).  
152 NR NR T3-4, 
N1-3 
LRR, DM NR Unadjusted 
Ly 2012* [30] Retrospective Retrospective study of 
TNBC patients with early 
62 NR 3.3  T1-2, LRR, DM Excluded 
patients with 
Unadjusted  
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Study ID & 
country/region 
Study design TNBC study population Study 
size 
(TNBC 
cases) 
Age 
(years) 
 Follow-
up time 
(years) 
Stage 
of 
disease 
Survival 
estimates 
Chemotherapy 
 
Adjustments 
USA cohort study stage disease treated at the 
Jackson Memorial Hospital, 
Miami (FL) from 2004 to 
2010.  
N0-1  
 
NCT.  
72.6% CT 
Steward 2014 
[24] USA 
Retrospective 
cohort study 
Retrospective study of 
TNBC patients from a 
prospectively maintained 
database with a diagnosis of 
stage I-III disease who were 
treated between Jan 1, 2002 
and Dec 31, 2009.  
 
468 Average: 
54 
Median: 
4.3 
T1-4, 
N0-3 
OS 32% NCT 
50% CT 
A backward selection model 
was chosen (p<0.15). Only 
stage (1, 2a, 2b, 3 and 
unknown) was significant in 
the multivariable model. 
Other variables considered 
included age (<50, >=50), 
ethnicity, clinical T stage, 
histology, nuclear grade and 
nodal status.  
Tseng 2015 
[25] USA 
Retrospective 
cohort study 
Non-metastatic TNBC 
diagnosed from 1997 to 
2012 at one of 9 
participating National 
Comprehensive Cancer 
Network institutions 
including: City of Hope 
comprehensive cancer 
centre, Dana-
Farber/Brigham and 
Women’s cancer centre, 
Massachusetts General 
Hospital, Fox Chase Cancer 
Centre, The University of 
Texas MD Anderson cancer 
centre, Roswell Park cancer 
institute, University of 
Michigan, Ohio State 
University comprehensive 
695 Average: 
52   
Median: 
4.2 
T1-4, 
N0-3 
LRR Excluded 
patients with 
NCT 
Number of positive lymph 
nodes, tumour size, surgical 
margin.  
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Study ID & 
country/region 
Study design TNBC study population Study 
size 
(TNBC 
cases) 
Age 
(years) 
 Follow-
up time 
(years) 
Stage 
of 
disease 
Survival 
estimates 
Chemotherapy 
 
Adjustments 
cancer centre and Duke 
comprehensive cancer 
centre.   
Wang 2011 [27] 
China 
Randomised 
Controlled 
Trial 
Multi-centre trial of 
consecutive patients with 
TNBC stage I-II breast 
cancer enrolled between 
February 2001 and February 
2006. 
681 NR Median 
7.2 
T1-2, 
N0-3 
OS 54% CT Unadjusted 
Zumsteg 2013 
[29] USA 
Retrospective 
cohort study 
TNBC patients identified 
from clinical pathology 
reports (an institutional 
database). These were 
consecutive patients treated 
at a single institution 
(Memorial Sloan-Kettering 
Cancer Centre) from 1999 to 
2008.  
646 Median: 
59 
Median 
6.5 
T1-2, 
N0 
 
OS, DM, 
LRR, DFS 
Excluded 
patients with 
NCT. 81.3% CT 
Age (>50, <=50), Race 
(black vs non-black), T stage 
(Tmic/T1a/T1b, T1c, T2) LVI 
(yes vs. no), Grade (3 vs. 1 
or 2), Chemotherapy (yes vs. 
no).  
* Conference abstracts only.  
NR = not reported, TNBC = triple negative breast cancer, LRR= local regional recurrence, DM = distant metastases, DFS= disease-free survival, CT= adjuvant chemotherapy, 
NCT = neo-adjuvant chemotherapy, PMRT=post mastectomy radiotherapy 
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Table 2 (online only): Literature search strategy example  
MEDLINE: 1946-Week 4 October 2015, Limited to publications from 2000 onwards  
 
1 Breast/ or Breast Neoplasms/ or Triple Negative Breast Neoplasms/ 
2 breast cancer.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] 
3 1 or 2 
4 breast conserving therapy.mp. 
5 breast conserving surgery.mp. or Mastectomy, Segmental/ 
6 breast conservation.mp. 
7 breast preservation.mp. 
8 breast sparing surgery.mp. 
9 wide local excision.mp. 
10 lumpectomy.mp. or Mastectomy, Segmental/ 
11 quadrantectomy.mp. 
12 Mastectomy, Subcutaneous/ or Mastectomy, Extended Radical/ or Mastectomy/ or 
Mastectomy, Radical/ or mastectomy.mp. or Mastectomy, Modified Radical/ or 
Mastectomy, Simple/ 
13 Fatal Outcome/ or outcome.mp. 
14 Disease-Free Survival/ or Survival/ or survival.mp. 
15 Recurrence/ or Neoplasm Recurrence, Local/ or recurrence.mp. 
16 overall survival.mp. 
17 cancer specific survival.mp. 
18 cause specific survival.mp. 
19 recurrence free survival.mp. 
20 locoregional control.mp. 
21 mortality.mp. or Mortality/ 
22 Disease Progression/ or progression.mp. 
23 prognosis.mp. or Prognosis/ 
24 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 
25 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 
26 basal like.mp. 
27 triple negative.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] 
28 26 or 27 
29 3 and 24 and 25 and 28 
30 limit 29 to yr="2000 -Current" 
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Table 3 (online only): Methodological quality assessment of cohort studies [33] included in 
the systematic review and meta-analysis 
 Methodological quality assessment  
 Selection Comparability Outcome  
Study ID A B C D E F G H I Total 
score† 
Abdulkarim 2011 17 - * * * * * * * - 7 
Bhoo-Pathy 2015 18 * * * * * * * * - 8 
Chen 2013 22 - * * * * * * * - 7 
Cruz 2014 19 - * * * - - * * - 5 
Dragun 2011 21 - * * * - - * - * 5 
Eastman 2012 20 - * * * - - * - - 4 
Ly 2012 30 - * * * - - * * - 5 
Steward 2014 24 - * * * * * - * - 6 
Tseng 2015 25 * * * * * * * * - 8 
Zumsteg 2013 29 - * * * - * * * - 6 
Selection (4*): 
A = Representativeness of the exposed cohort 
B = Selection of the non-exposed cohort 
C = Ascertainment of exposure 
D = Outcome of interest not present at the start 
Comparability (2*): 
E = Comparability – axillary node status 
F = Comparability – tumour size or stage 
Outcome (3*): 
G = Assessment of outcome 
H = Was follow-up long enough 
I = Adequacy of follow-up 
 
† A total of 9 points can be awarded, 4 for selection, 2 for comparability and 3 for outcome. 
 
Table 4 (online only): Methodological quality assessment of randomised controlled trials 
[34] included in the systematic review and meta-analysis 
 Risk of bias 
Study ID A B C D E F G 
Kyndi 2008 23        
Wang 2011 27        
A = Random sequence generation  
B = Allocation concealment  
C = Blinding of participants & personnel 
D = blinding of outcome assessment  
E = Incomplete outcome data  
F = Selective reporting  
G = Other bias   
 Key:  
 Low risk of bias 
High risk of bias  
Unclear risk of bias  
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